Reduced-intensity allogeneic stem cell transplantation is an effective salvage
treatment for relapsed aggressive non-Hodgkin’s lymphoma
P. Corradini1, A. Dodero1, M. Bregni4, A. Olivieri5, P. Valagussa1, L. Farina1
R. Milani1, R. Scimé10 , A. Rambaldi6, F. Bonifazi7, F. Patriarca8, A. Locasciulli9
A. Bacigalupo11, A.M. Gianni2, C. Tarella3 on behalf of GITMO
1Hematology division and 2Medical Oncology Division, Istituto Nazionale Tumori,
University of Milano; 3Hematology division, University of Torino; 4Hematology division,
S. Raffaele; 5Hematology division, University of Ancona; 6Hematology division, Bergamo; 7Hematology division, Bologna; 8Hematology division, Udine; 9Hematology division,
Osp. S Camillo, Roma; 10Hematology division, Palermo; 11Hematology division 2,
San Martino, Genova, Italy
We conducted a multicenter phase II trial for salvage treatment of relapsed lymphomas; 170 pts received allogeneic SCT from HLA identical sibling donors at 22 italian centers. RIC regimen included thiotepa, fludarabine and cyclophosphamide. GVHD prophylaxis consisted of cyclosporine A and short-course methotrexate.
[>Read full article in PDF]